Physician Briefing
- Allergy
- Anesthesiology
- Cardiology
- Cosmetic Surgery
- Critical Care
- Dermatology
- Diabetes & Endocrinology
- Emergency Medicine
- Family Practice
- Gastroenterology
- Geriatrics
- Hematology & Oncology
- HIV & AIDS
- Infectious Disease
- Internal Medicine
- Nephrology
- Neurology
- Nursing
- OBGYN & Women's Health
- Oncology
- Ophthalmology
- Orthopedics
- Otolaryngology
- Pain Management
- Pathology
- Pediatrics
- Pharmacy
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Surgery
- Urology
Pharmacy News
-
Sunscreen Ingredient May Be Linked to Risk of Endometriosis
Benzophenone-type derivatives may be linked to an increased risk of endometriosis, according to a study published in the April 17 issue of Environmental Science & Technology.
-
ASCO: Crizotinib Tolerated, Active in Pediatric Patients
For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase gene, crizotinib is well tolerated and has antitumor activity, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
-
Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma
For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events, and pain, but bisphosphonates do not appear to improve overall survival, with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving overall survival, according to a review and meta-analysis published online May 16 in the The Cochrane Library.
-
ASCO: For Chemo's Nausea, Olanzapine Beats Metoclopramide
For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment with metoclopramide, according to a phase III study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
-
ASCO: Dabrafenib/Trametinib Active in Metastatic Melanoma
For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
-
ASCO: Abiraterone Tolerated in High-Risk Prostate Cancer
For men with localized high-risk prostate cancer, neoadjuvant androgen deprivation therapy with abiraterone acetate plus leuprolide acetate is well tolerated and has good pathological complete/near complete response rates, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
Pharmacy Conference Highlights
- American Psychiatric Association, May 5-9, 2012
- American Association for Cancer Research, March 31-April 4, 2012
- American College of Cardiology, March 24-27, 2012
- American Academy of Dermatology, March 16-20, 2012
- Society of Critical Care Medicine, Feb. 4-8, 2012
More Pharmacy Conference Highlights